Blog

NHMRC backs puberty blockers for trans kids

Australia’s top researchers have conditionally recommended the use of puberty blockers in young people experiencing gender dysphoria, but health minister Mark Butler warns he cannot force Queensland and the Northern Territory to lift bans on the treatment. 
The conditional recommendation from the National Health and Medical Research Council is particularly surprising given that the UK’s 2024 Cass review of gender identity services found that evidence for the use of the drugs was too weak.  
When asked to explain why the NHMRC guidance would differ from that of the Cass review, Mr Butler said Australia’s models of care could not be directly compared to that of the UK.  
“I have the utmost respect for the National Health and Medical Research Council,” he said.  
“The role that it has long played in this country is at arm’s length from the government of the day and from the political process, to provide the highest quality clinical advice to health practitioners and the community more generally.  
“[It] should always be respected, and that’s why I asked them to review the evidence and issue some preeminent guidelines to guide this contested, evolving area that’s the subject of so much public commentary and involves some of our most vulnerable members of the community.  
“I’m not going to question the advice or make some sort of qualitative judgement about the advice of our most eminent clinicians that have been doing this, in terms of the difference to the Cass review.” 
At the beginning of 2025, Mr Butler tasked the NHMRC with developing clinical practice guidelines for the care of trans and gender diverse people aged under 18, with advice on the use of puberty suppressants to be prioritised.  
That advice was published today, and is open for consultation until 18 January 2027.  

Related   

CHO raises alarm over trans debate

Second legal challenge launched against puberty blockers ban

Why Queensland didn’t copy the UK approach to transgender care

It conditionally recommended puberty suppressants for young people aged under 18 with gender incongruence, as long as that person had already started puberty (defined as Tanner stage 2 or later), had been diagnosed with gender incongruence and had been assessed as suitable for treatment with gonadotropin-releasing hormone agonists.  
“The Gender Guidelines Development Committee suggests that, based on a shared decision between the young person, parents or carers and clinicians, gonadotropin-releasing hormone (GnRH) agonists can be considered for a young person who wants puberty suppression and who meets the … criteria,” the recommendation read.  
The larger clinical practice guidelines will look at the provision of psychosocial support to children and adolescents experiencing gender incongruence and the use of hormone treatments. These are not expected until early 2028.  
Mr Butler noted that puberty blockers were typically prescribed off-label for transgender children, and as such were not funded under the PBS.  
This was unlikely to change, he said.  
“There have not been the clinical trials and the evidence that is usually important to justify a reimbursement decision through the PBS, and you see that through Europe and the UK and other jurisdictions as well,” Mr Butler said.  
“We don’t propose to make any change to that. This would continue as an off-label prescribing practice.” 
There is little that Mr Butler, as federal health minister, can do to ensure that the NHMRC’s conditional recommendation is put into practice.  
Because multidisciplinary gender clinics tend to be run from public hospitals, states and territories hold the balance of power.  
State governments in Queensland and the Northern Territory have both banned gender clinics in their respective jurisdictions from prescribing puberty blockers to young people with gender dysphoria.  
When asked directly whether the federal government could intervene and force Queensland and the Northern Territory to follow the NHMRC recommendation, Mr Butler said its hands were tied.  
“The federal government can’t step in,” he said.  
“These are state-run services.  
“… Ultimately, the Queensland government is accountable to the Queensland people for the way in which they run all of their hospital services.  
“I am very confident that every state government, no matter their political persuasion, will consider the advice of our preeminent authority very closely.  
“Whether that leads to a change in policy by either the Queensland or NT government is really a matter for them.” 
Mr Butler also emphasised that NHMRC review had found Australia’s current systems were working well.  
“The NHMRC, in its advice, points to a series of data from a number of those services, including the [country’s largest service] in Melbourne, suggesting the prescription of puberty blockers [was limited] to maybe several dozen young people over the course of several years,” he said.  
“It also suggests that prescription of puberty blockers and hormones, for that matter, usually involve extensive periods of support that the clinic or the service has provided to young people.  
“In the Melbourne case … [this support is provided] on average for 530 days before any prescription of medicine is undertaken.” 
The Medical Republic has chosen to disable comments on this story. 
The post NHMRC backs puberty blockers for trans kids appeared first on Medical Republic.

About the author

Asonblog

Add Comment

Click here to post a comment